Treatment News : Selzentry Reduces Liver Stiffness in HIV/HCV-Coinfected Patients - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 21, 2011

Selzentry Reduces Liver Stiffness in HIV/HCV-Coinfected Patients

by Tim Horn

Just as people coinfected with HIV and hepatitis B virus (HBV) dually benefit from taking the antiretroviral Truvada (tenofovir plus emtricitabine), could people coinfected with HIV and hepatitis C virus (HCV) benefit from Selzentry (maraviroc)? Possibly, according to an important new study reported Wednesday, July 20, at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Rome.

Using noninvasive liver scanning, Paola Nasta, MD, and her colleagues at the University of Brescia in Brescia, Italy, found that the CCR5-blocking activity of Selzentry appears to minimize liver stiffness in people living with both viruses. Though the implications of this finding aren’t clear, it is potentially good news for coinfected individuals who either cannot take, or are hoping to delay, chronic HCV treatment using today’s side effect–prone regimens.

The study enrolled 54 coinfected people, all of whom were already on an antiretroviral (ARV) regimen for their HIV but hadn’t yet started treatment for their HCV. Twenty-eight study volunteers added Selzentry to their ARV regimen, consisting of Norvir (ritonavir)–boosted Reyataz plus Truvada. The remaining participants served as a control group.

Volunteers were, on average, 46 years old. Most were men with CD4 counts averaging 500 cells. More than 90 percent of those enrolled had hard-to-treat HCV genotypes 1 or 4.

All participants underwent FibroScan testing, an ultrasound-based measure of liver stiffness, upon entering the study and six months later. Though FibroScan results can be roughly translated into the universal standard of fibrosis staging—METAVIR scoring based on the liver biopsy results—there is some controversy regarding the sensitivity of the test. It appears most effective at detecting advanced fibrosis (cirrhosis) and is less sensitive in detecting mild or moderate fibrosis. 

Across the board, FibroScan-translated METAVIR scores, which range from “F0” (no fibrosis) to “F4” (cirrhosis), neither improved nor worsened in the majority of people in both groups, with more in the Selzentry group holding steady. Where changes in fibrosis scores were noted, they were more likely to be improvements among those taking Selzentry and worsening liver stiffness among those in the control group.

Among those who didn’t add Selzentry and had evidence of a change in liver stiffness, there was a drop in the number of people with a score of F1 (57 to 47 percent), and their liver stiffness moved on to a score of F2 or higher. Conversely, there was an increased number of participants with a score of F1 in the Selzentry group (35 to 44 percent), reflecting a reduced number of participants with more advanced fibrosis scores upon starting the study.

Nasta noted that HCV viral loads remained, for the most part, unchanged in the study. The way in which Selzentry potentially worked in her group’s study is unclear, though she noted in her introductory remarks that CCR5—the same protein, or chemokine, that plays a role in HIV entry into cells—among other chemokines may play a role in the way liver scarring occurs, according to studies involving mice.

Curiously, some studies have suggested that the same CCR5 mutation that confers immunity to HIV, or at least slows its disease progression, may actually increase the chances of HCV becoming chronic in people living with the virus. In turn, more research will ultimately be needed to understand the benefits—and potential pitfalls—of using CCR5-targeting ARVs to manage HCV infection and its effects on the liver.

Search: Selzentry, Celsentri, maraviron, fibrosis, METAVIR, FibroScan, transiet elastography, CCR5, IAS, Rome


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dlw8585
    Fort Lauderdale
    Florida


    usuallyhappy
    Palm Springs
    California


    cortaza100
    Oakland
    California


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.